Eli Lilly will acquire clinical-stage biopharmaceutical company AtaiBeckley for an upfront payment of $2.8 billion.
Eli Lilly will acquire AtaiBeckley for $2.8 billion upfront, a move that provides the pharmaceutical giant with access to experimental psychedelic therapies for mental health. The deal, which offers a 26% premium over the previous closing price, includes the potential for an additional $1 billion in payments if specific clinical and regulatory milestones are met. The acquisition focuses on AtaiBeckley's DMT-based nasal spray, currently in Phase 3 clinical trials for treatment-resistant depression. Unlike conventional antidepressants that primarily alter neurotransmitters, these therapies aim to restore synaptic connectivity and promote the growth of new neural connections. Dan Skovronsky, chief scientific officer at Eli Lilly, noted that the drug could provide profound effects quickly that persist for months. The transaction highlights growing momentum in the psychedelic drug market. The administration has prioritized the development of psychedelic-based treatments for conditions such as depression and post-traumatic stress disorder. This deal is part of a larger spending spree for Eli Lilly, which plans to spend up to $25 billion on eight acquisitions this year.